Pharmaceutical companies Nektar Therapeutics and Bristol-Myers Squibb have expanded their collaboration to develop an anti-cancer treatment.
The treatment comprises Nektar’s bempegaldesleukin (bempeg) and Bristol-Myers' Opdivo (nivolumab). The expansion would go beyond the three pivotal studies in first-line metastatic melanoma, first-line cisplatin-ineligible metastatic urothelial cancer and first-line metastatic renal cell carcinoma (RCC) - to include additional trials in adjuvant melanoma and in muscle-invasive bladder cancer. Nektar and Bristol-Myers will also begin phase 1/2 dose escalation studies in first-line RCC.
The two companies began the partnership in 2016. The cost-sharing conditions won’t change in the expanded accord.
Bristol-Myers will also fund a Phase 1/2 dose optimization and expansion trial assessing the combo in first-line non-small cell lung cancer.
Nektar will be able to receive up to $125 million total once the first patients are dosed in the adjuvant melanoma trial ($25 million), muscle-invasive bladder cancer trial ($25 million), and NSCLC trial ($75 million).